NervGen Pharma Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for NervGen Pharma.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth	72.3%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	Low
Last updated	30 Apr 2024

Recent future growth updates

Recent updates

NervGen Pharma Corp. (CVE:NGEN) Shares Could Be 31% Below Their Intrinsic Value Estimate

Feb 02

We're Keeping An Eye On NervGen Pharma's (CVE:NGEN) Cash Burn Rate

Nov 23

We Think NervGen Pharma (CVE:NGEN) Needs To Drive Business Growth Carefully

Jun 29

We're Not Very Worried About NervGen Pharma's (CVE:NGEN) Cash Burn Rate

Mar 16

We're Keeping An Eye On NervGen Pharma's (CVE:NGEN) Cash Burn Rate

Mar 08

Earnings and Revenue Growth Forecasts

TSXV:NGEN - Analysts future estimates and past financials data (CAD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	N/A	N/A	N/A	N/A	1
12/31/2025	N/A	N/A	-22	-22	1
12/31/2024	N/A	N/A	-15	-15	1
3/31/2024	N/A	-20	-10	-10	N/A
12/31/2023	N/A	-22	-11	-11	N/A
9/30/2023	N/A	-20	-13	-13	N/A
6/30/2023	N/A	-19	-17	-17	N/A
3/31/2023	N/A	-20	-18	-18	N/A
12/31/2022	N/A	-21	-18	-18	N/A
9/30/2022	N/A	-19	-16	-16	N/A
6/30/2022	N/A	-19	-13	-13	N/A
3/31/2022	N/A	-15	-11	-11	N/A
12/31/2021	N/A	-13	-8	-8	N/A
9/30/2021	N/A	-13	-7	-7	N/A
6/30/2021	N/A	-12	-7	-6	N/A
3/31/2021	N/A	-12	-6	-6	N/A
12/31/2020	N/A	-11	-6	-6	N/A
9/30/2020	N/A	-10	-6	-6	N/A
6/30/2020	N/A	-10	-7	-7	N/A
3/31/2020	N/A	-9	-7	-7	N/A
12/31/2019	N/A	-10	-8	-8	N/A
9/30/2019	N/A	-8	-7	-7	N/A
6/30/2019	N/A	-6	-5	-5	N/A
3/31/2019	N/A	-4	-4	-4	N/A
12/31/2018	N/A	-1	-1	-1	N/A
9/30/2018	N/A	-1	0	0	N/A
6/30/2018	N/A	0	0	0	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if NGEN's forecast earnings growth is above the savings rate (2.1%).

Earnings vs Market: Insufficient data to determine if NGEN's earnings are forecast to grow faster than the Canadian market

High Growth Earnings: Insufficient data to determine if NGEN's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if NGEN's revenue is forecast to grow faster than the Canadian market.

High Growth Revenue: NGEN is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if NGEN's Return on Equity is forecast to be high in 3 years time

NervGen Pharma Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target increased by 8.6% to CA$6.00

Recent updates

NervGen Pharma Corp. Approves Board and Audit Committee Elections

New minor risk - Market cap size

New major risk - Negative shareholders equity

CEO, President & Director recently bought CA$338k worth of stock

NervGen Pharma Corp., Annual General Meeting, Jun 04, 2024

New minor risk - Market cap size

Independent Director exercised options to buy CA$272k worth of stock.

Co-Founder & Independent Director exercised options to buy CA$347k worth of stock.

New minor risk - Share price stability

Is NervGen Pharma (CVE:NGEN) In A Good Position To Invest In Growth?

NervGen Pharma Corp. Receives Fast Track Designation for NVG-291 for the Treatment of Individuals with Spinal Cord Injury

Nervgen Pharma Appoints John Ruffolo to Board of Directors

NervGen Pharma Corp. Announces First Subject Dosed in Landmark Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury

Here's Why We're Watching NervGen Pharma's (CVE:NGEN) Cash Burn Situation

Price target increased by 8.6% to CA$6.00

Will NervGen Pharma (CVE:NGEN) Spend Its Cash Wisely?

NervGen Pharma Announces Completion of Dosing of All Subjects in Phase 1 Clinical Trial of Proprietary Drug Candidate NVG-291

NervGen Pharma Corp. (CVE:NGEN) Shares Could Be 31% Below Their Intrinsic Value Estimate

We're Keeping An Eye On NervGen Pharma's (CVE:NGEN) Cash Burn Rate

High number of new and inexperienced directors

Nervgen Pharma Corp. Receives FDA Authorization to Expand Enrollment of Males and Premenopausal Females in Phase 1 Clinical Trial of NervGen's NVG-291

NervGen Pharma Corp. Receives Up to $1.5 Million US Department of Defense Funding to Evaluate NervGen's NVG-291-R for Peripheral Nerve Injury

NervGen Pharma Corp. Announces Executive Changes

NervGen Pharma Corp., Annual General Meeting, Sep 28, 2022

NervGen Pharma Corp. announced that it has received $15.225 million in funding from PFP Biosciences Holdings

NervGen Pharma Corp. Appoints Adam Rogers to its Board of Directors

NervGen Pharma Corp. announced that it expects to receive $15.225 million in funding

We Think NervGen Pharma (CVE:NGEN) Needs To Drive Business Growth Carefully

Nervgen Pharma Corp. Receives Approval from the Safety Review Committee to Advance to the Third and Highest Dose Cohort in the Multiple Ascending Dose Portion of Phase 1 Clinical Trial of the Company's Proprietary Lead Compound, NVG-291

President exercised options to buy CA$112k worth of stock.

Independent Director exercised options to buy CA$224k worth of stock.

Less than half of directors are independent

NervGen Pharma Corp. Announces Executive Changes

We're Not Very Worried About NervGen Pharma's (CVE:NGEN) Cash Burn Rate

High number of new directors

NervGen Pharma Corp. announced that it has received CAD 2.321075 million in funding

NervGen Pharma Corp. announced that it has received CAD 2.343036 million in funding

NervGen Pharma Corp. has completed a Composite Units Offering in the amount of CAD 5.0375 million.

NervGen Pharma Announces First Subject Dosed in Phase 1 Clinical Trial of NVG-291

We're Keeping An Eye On NervGen Pharma's (CVE:NGEN) Cash Burn Rate

NervGen Pharma Corp. Provides Regulatory Update on Development Program for NVG-291

Nervgen Pharma Adds Alzheimer's Disease Patient Cohort to Its Phase 1 Clinical Trial Program

New 90-day high: CA$2.41

New 90-day high: CA$1.90

New 90-day high: CA$1.85

NervGen Pharma Corp. Appoints Dr. Randall Kaye to the Company's Board of Directors

NervGen Pharma Corp. Provides an Update on NVG-291

New 90-day low: CA$1.43

New 90-day low - CA$1.52

NervGen Pharma Corp. has completed a Composite Units Offering in the amount of CAD 6.45 million.

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies